	US 12,239,645 B2
	Targeted dosing for the treatment of complement mediated disorders
Mingjun Huang, Vancouver, WA (US); and Steven D. Podos, New Haven, CT (US)
Assigned to Achillion Pharmaceuticals, Inc., Boston, MA (US)
Appl. No. 17/414,057
Filed by Achillion Pharmaceuticals, Inc., Boston, MA (US)
PCT Filed Dec. 17, 2019, PCT No. PCT/US2019/066999 § 371(c)(1), (2) Date Jun. 15, 2021, PCT Pub. No. WO2020/131974, PCT Pub. Date Jun. 25, 2020.
Claims priority of provisional application 62/780,573, filed on Dec. 17, 2018.
Claims priority of provisional application 62/877,193, filed on Jul. 22, 2019.
Prior Publication US 2022/0079943 A1, Mar. 17, 2022
Int. Cl. A61K 31/506 (2006.01); A61K 9/00 (2006.01); A61P 7/06 (2006.01)

CPC A61K 31/506 (2013.01) [A61K 9/0053 (2013.01); A61P 7/06 (2018.01)]

13 Claims

1. A method of modulating immune function in a patient in need thereof, the method comprising administering to the patient (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0] hexane-3-carboxamide (Compound 1), or a pharmaceutically acceptable salt thereof, at a dosage of between about 100 mg and about 200 mg twice a day (BID).